Clinical Trials

Eureka is conducting the following clinical trials for patients with liver cancer:

Adults

ARYA-1: A Study of ET140203 T Cells in Adult Subjects with AFP+ Liver Cancer.

A phase 1/2 clinical trial of ET140203 T cells in adult subjects with advanced Hepatocellular Carcinoma (HCC). The study includes a dose escalation and expansion phase and will be conducted at multiple sites.

Study Status: This study is currently recruiting participants. For additional information, please visit clinicaltrials.gov

PEDIATRICS

ARYA-2: A Study of ET140203 T Cells in Pediatric Subjects with AFP+ Liver Cancer.

A phase 1/2 clinical trial of ET140203 T cells in pediatric subjects with relapsed/refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC). The study includes a dose escalation and expansion phase and will be conducted at multiple sites.

Study Status: This study is currently pending site activation. For additional information, please visit clinicaltrials.gov

adults

ARYA-3: A Study of ECT204 T Cells in Adult Subjects with GPC3+ Liver Cancer.

A phase 1/2 clinical trial of ECT204 T cells in adult subjects with advanced Hepatocellular Carcinoma (HCC). The study includes a dose escalation and expansion phase and will be conducted at multiple sites.

Study Status: This study is currently recruiting participants. For additional information, please visit clinicaltrials.gov

The Patient and T Cell Journey

Your T cells, fighting your specific type of cancer. See the schematic below to learn more about the patient and T cell journey.

To learn more about participating in our clinical trials, click the link below.

Contact Us

EUREKA THERAPEUTICS, ARTEMIS, and E-ALPHA are registered trademarks owned by Eureka Therapeutics, Inc.